Vaisala Group
28.7.2026 13:00:00 CEST | Globenewswire | Press release
Change in Vaisala Corporation’s number of series A and K shares
Change in Vaisala Corporation’s number of series A and K shares
Vaisala Corporation
Stock exchange release
July 28, 2026, at 2:00 p.m. EEST
Change in Vaisala Corporation’s number of series A and K shares
Vaisala Corporation’s Board of Directors decided at its meeting on July 20, 2026, that 1,200 series K shares would be converted into series A shares. This conversion was registered in the Trade Register today, July 28, 2026.
Consequently, Vaisala has 36,436,728 shares, of which 3,091,928 are series K shares and 33,344,800 are series A shares. The total number of votes attached to all shares is 95,183,360.
Vaisala holds a total of 153,420 of the company’s series A shares, which represent 0.46% of the series A shares and 0.42% of all shares.
More information
Niina Ala-Luopa, investor relations
+358 400 728 957, ir@vaisala.com
Distribution
Nasdaq Helsinki
Key media
vaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With over 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. www.vaisala.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ZenaTech Inc.28.7.2026 13:30:00 CEST | Press release
ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform
Lantronix, Inc.28.7.2026 13:00:00 CEST | Press release
Lantronix Announces DoD Solution Partnership to Deploy Edge AI Drone Platform in Ukraine
OKYO Pharma LTD28.7.2026 13:00:00 CEST | Press release
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
The CSL Group Inc28.7.2026 13:00:00 CEST | Press release
CSL Marks the Completion of the First Vessel in World-Leading Transhipment Fleet for Simandou Project
ProMIS Neurosciences Inc.28.7.2026 12:00:00 CEST | Press release
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom